Pascual Juan M, Campistol Jaume, Gil-Nagel Antonio
Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, Texas, USA.
Neurologist. 2008 Nov;14(6 Suppl 1):S2-S14. doi: 10.1097/01.nrl.0000340787.30542.41.
The study of neurometabolic diseases is still in a prolonged preliminary stage. The catalogue of these diseases continues to grow; some known clinical syndromes have been subdivided into a number of variants once the genes that cause them have been identified, and at the same time new metabolic disorders have been discovered that aggravate or contribute to forms of epilepsy not previously classified as cerebral metabolic disorders.
This review presents the basic principles underlying the recognition and treatment of epilepsy caused by neurometabolic diseases. These disorders are divided (purely for the sake of convenience) into epilepsy presenting in newborn infants, children, and adolescents and adults, recognizing that there is a significant degree of overlap between these chronological stages. Current analytical methods and therapeutic approaches are summarized both from a general point of view and within the context of each clinical syndrome, acknowledging that each patient presents specific peculiarities and that, in general, antiepileptic drugs provide few benefits compared with more specific types of therapy (eg, special diets or vitamins) when indicated. We also include therapeutic recommendations and a general approach to fulminant epilepsies of neurometabolic origin, emphasizing the importance of identifying all of the proband's relatives who may be potential carriers of a genetic disorder during the diagnostic and genetic counselling process. Particular emphasis is placed on disorders for which there is curative treatment and on the importance of follow-up by expert professionals.
It is expected that in a few years' time it will be possible to know the metabolomic profile of these diseases (possibly by non-invasive methods), thus facilitating accurate diagnosis and making it possible to establish the response to treatment and to identify all individuals who are carriers or remain minimally symptomatic in terms of their risk of manifesting or transmitting epilepsy.
神经代谢性疾病的研究仍处于长期的初步阶段。这类疾病的种类不断增加;一旦导致某些已知临床综合征的基因被确定,其中一些综合征就被细分为多个变体,与此同时,还发现了一些新的代谢紊乱,这些紊乱会加重或导致以前未归类为脑代谢紊乱的癫痫形式。
本综述介绍了神经代谢性疾病所致癫痫的识别和治疗的基本原则。为方便起见,这些疾病被分为新生儿期、儿童期、青少年期和成人期出现的癫痫,同时认识到这些按时间顺序划分的阶段之间存在很大程度的重叠。从一般角度以及在每种临床综合征的背景下总结了当前的分析方法和治疗方法,承认每个患者都有其独特之处,并且一般来说,与更具针对性的治疗方法(如特殊饮食或维生素)相比,抗癫痫药物在有指征时益处不大。我们还纳入了治疗建议以及针对神经代谢性起源的暴发性癫痫的一般方法,强调在诊断和遗传咨询过程中识别所有可能是遗传疾病潜在携带者的先证者亲属的重要性。特别强调了有治愈性治疗的疾病以及专家专业人员随访的重要性。
预计在几年内将有可能了解这些疾病的代谢组学特征(可能通过非侵入性方法),从而便于准确诊断,并能够确定对治疗的反应以及识别所有携带者或在癫痫发作或传播风险方面症状轻微的个体。